ANTIBIOTICE IASI
78 articole · RSS
Antibiotice Invests in Research and New Drug Production Lines
Antibiotice Iasi, the largest Romanian-owned drug producer, has investment projects underway and will further develop the research center and new production lines for drug that do not have a...
Antibiotice Iasi Has EUR50M Worth of Investments Underway in Three New Production Capacities
Antibiotice Iasi, the largest Romanian-owned drugmaker, a company controlled by the Romanian state via the Health Ministry, plans to add three new production capacities and investments under...
Antibiotice Iasi H1/2025 Net Profit Down 20% YOY To RON59M
Generic drug manufacturer Antibiotice Iasi, controlled by the Romanian state via the Health Ministry, ended the first six months of 2025 with RON59 million net profit, down 20% from the year...
Antibiotice Iasi To Supply 7 million Vials Of Injectable Antibiotics To Hospitals In the UK Over Next Two Years
State-owned pharmaceutical producer Antibiotice Iasi (ATB.RO) has announced in a stock market report on June 5 that it recently won the 5th tender organized by the National Health Service (N...
Antibiotice Iasi Q1/2025 Revenues Down 6% To RON180M; Net Profit Falls 13% To RON32.6M
Pharma producer Antibiotice Iasi in the first quarter of this year generated total revenues of RON180 million, down 6%, and net profit of RON32.6 million, 13% lower than the year-earlier lev...
Antibiotice Iasi Wants to Distribute RON13.8M Worth of Dividends
Romanian drug manufacturer Antibiotice Iasi has proposed the distribution of RON13.8 million worth of dividends from the 2024 net profit reported on the basis of annual audited financial sta...
Antibiotice Iasi 2024 Revenues Up 8% To RON693M, Net Profit Rises 23% To RON99M
Romanian drug manufacturer Antibiotice Iasi in 2024 registered total revenues worth RON693 million, up 8%, and RON99 million net profit, 23% above the 2023 level.
Antibiotice Iasi Aims to Invest RON850M by 2030
Romanian drug manufacturer Antibiotice Iasi has a RON850 million investment plan until 2030, covered through a funding mix, made up of cohesion funds, state aid, PNRR funds and EIB loan, sta...
Antibiotice Iasi Reports RON74M Net Profit For H1/2024, Up 20% YoY
Romanian-owned drug manufacturer Antibiotice Iasi (stock symbol: ATB) ended the first half of 2024 with net profit of RON74 million, up 20% on the year, while its revenue rose by 8% to RON38...